PIK3CD and triple-negative breast carcinoma: In a clinical trial for brain-metastatic triple-negative breast cancer (NCT01629615), clinical benefit from PI3K inhibition was observed in only 12% of patients, with significant toxicities, including hyperglycemia, rash, and fatigue, similar to those seen with other pan-PI3K inhibitors [67].